SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D++ financing of RMB 250 million. This round of financing was co-invested by a renowned corporate venture capital and a well-known insurance fund. Ark Capital is the sole financial advisor of this financing round.
The proceeds from this round will support the commercialization of the core product Senaparib, which has demonstrated best-in-class potential in clinical pivotal phase III study, and accelerate the global clinical development of multiple compounds, including our novel PARP1 selective inhibitors, and the development of multiple early pre-clinical projects.
“We are pleased to announce the successful completion of our Series D++ financing and would like to express our sincere gratitude to our new investors for their support and trust in IMPACT, and to our existing shareholders for their support along the way in the development of our company!" said Dr. Sui Xiong Cai, Chief Executive Officer of IMPACT.
“With more than ten years of dedicated R&D efforts, IMPACT has built an integrated synthetic lethal R&D platform. We believe that Senaparib, with its best-in-class potential, backed up by the strong marketing network and professional promotion experience of our commercialization partner, Huadong Medicine, will benefit more ovarian cancer patients soon. Senaparib will bring a new and better choice of first-line maintenance therapy for ovarian cancer patients.”
About Senaparib
Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window. The Phase III registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint. In August 2022, the fixed dose combination capsules of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA). In August 2023, the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Senaparib in China.
About IMPACT Therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT’s pipeline products include PARP inhibitor Senaparib (IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064), and PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics), as well as other novel DDR pathway inhibitors.
The most advanced development program, PARP inhibitor Senaparib (IMP4297), has been in clinical Phase II/III studies globally, including China, in ovarian cancer, small cell lung cancer and other indications. The Phase III clinical study of Senaparib for advanced ovarian cancer maintenance treatment following first-line therapy met primary endpoint, with best-in-class efficacy and safety profile, and its NDA has been accepted by the National Medical Products Administration (NMPA).
The Wee1 inhibitor IMP7068 and the ATR inhibitor IMP9064 have been investigated in Phase I clinical studies in several countries and regions around the world, including U.S. and China, and the recommended Phase II dose (RP2D) has been established. PARP1 selective inhibitor IMP1734 has obtained IND clearance from FDA and NMPA, as well as completed FPI in early 2024.
For additional information, please visit www.impacttherapeutics.com/en/.
IMPACT Therapeutics Contact:
+86 21 6841 1121
IR@impacttherapeutics.com